IVERIC bio — Conference Presentation (September 2022)
14 slides from IVERIC bio's conference presentation, Sep 28, 2022
Slide 1: Avacincaptad Pegol in Geographic Atrophy
1 AVACINCAPTAD PEGOL IN GEOGRAPHIC ATROPHY DHAVAL DESAI SVP & CHIEF DEVELOPMENT OFFICER Avacincaptad Pegol is an investigational product that has not been evaluated for safety and efficacy by the FDA
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Any statements in this presentation about IVERIC bio (the Company)’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statem
Slide 3: GATHER clinical program evaluated avacincaptad pegol vs. sham in identical GA patient populations
3 GATHER clinical program evaluated avacincaptad pegol vs. sham in identical GA patient populations
Slide 4: GATHER2 phase 3 study design
Phase 3, international, multicenter, prospective, randomized, double-masked, sham-controlled study (NCT04435366) 4*448 randomized, with 447 treated (one patient in sham not receiving treatment after randomization). Sham (N=222) Primary Endpoint Mean rate of in geographic atrophy growth (slope) from
Slide 5: Primary endpoint achieved at year one with a high degree of statistical significance
Primary endpoint (slope analysis) achieved at year one with a high degree of statistical significance 5ACP, avacincaptad pegol; CI, confidence interval; GA, geographic atrophy. 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 Baseline Month 12 M ea n Ra te o f G A G ro w th (S lo pe ) Fr om B as el in e
Slide 6: Prespecified slope analysis using observed data consistent with primary analysis
Prespecified (slope) analysis utilizing observed dataa was consistent with primary analysis 6 anon-square root transformation; bDescriptive p-value ACP, avacincaptad pegol; CI, confidence interval; GA, geographic atrophy. 0.00 0.50 1.00 1.50 2.00 Baseline Month 12 M ea n Ra te o f G A G ro w th (S l
Slide 7: Prespecified subgroup analysis shows benefit in all subgroups
Prespecified subgroup analysis shows benefit of avacincaptad pegol in all prespecified subgroups 7ACP, avacincaptad pegol; CI, confidence interval; FAF, Fundus Autofluorescence; GA, geographic atrophy; LS, least squares; VA, visual acuity. Subgroup n Growth Rate n Growth Rate Difference (CI) Baselin
Slide 8: GATHER1 subgroup analysis at 12 months
8ACP, avacincaptad pegol; CI, confidence interval; FAF, Fundus Autofluorescence; GA, geographic atrophy; LS, least squares; NE, not estimated; VA visual acuity. -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 LS Mean Difference (95% CI) Subgroup n LS Mean n LS Mean Difference (CI) Baseline GA <4 disc area 48 0.33 70
Slide 9: Benefit across subgroups seen in GATHER1 increases with duration of therapy
Benefit across subgroups seen in GATHER1 increases with duration of therapy 9ACP, avacincaptad pegol; CI, confidence interval; FAF, Fundus Autofluorescence; GA, geographic atrophy; LS, least squares; NE, not estimated; VA visual acuity. Subgroup n LS Mean n LS Mean Difference (CI) Baseline GA <4 dis
Slide 10: Study eye cases of intraocular inflammation, endophthalmitis, or ischemic optic neuropathy
10ACP, avacincaptad pegol. Intraocular inflammation, n 0 0 Endophthalmitis, n 0 0 Ischemic optic neuropathy, n 0 0 ACP 2 mg (N=225) Sham (N=222) Study eye cases of intraocular inflammation, endophthalmitis, or ischemic optic neuropathy
Slide 11: Comprehensive CNV surveillance program
11ACP, avacincaptad pegol; CNV, choroidal neovascularization; FA, Fluorescein angiography; FP, fundus photography; OCT, optical coherence tomography. Total CNV, n (%) 15 (6.7) 9 (4.1) ACP 2 mg (N=225) Sham (N=222) Comprehensive CNV surveillance program • Suspected development of CNV in the study eye
Slide 12: Exudative MNV in the study eye
12ACP, avacincaptad pegol; CNV, choroidal neovascularization; CORE, Center for Ocular Research and Evaluation; eMNV, exudative MNV; OCT, optical coherence tomography; MNV, macular neovascularization; neMNV, non-exudative MNV; RPE, retinal pigment epithelium. Total CNV, n (%) 15 (6.7) 9 (4.1) eMNV, n
Slide 13: First investigational GA therapy to achieve 12-month primary endpoint in two pivotal phase 3 studies
13ACP, avacincaptad pegol; CI, confidence interval; GA, geographic atrophy. 0.292 0.402 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0 6 12 ACP 2 mg (n=67) Sham (n=110) M ea n C ha ng e in G A A re a Fr om Ba se lin e (m m ) Difference (95% CI): 0.110 mm (0.030, 0.190) p=0.0072 Months 0.336 0.3
Slide 14: Thank you to the GATHER program investigators, research staff, and patients
Thank you to the GATHER program investigators, research staff, and patients 2 3 3 1 4 1 1 14 14 9 13 6 11 9 7 104 5 1 2 7 1 9 6 1 56 GATHER2 GATHER1
IVERIC bio — Conference Presentation (September 2022) on 6ix